Overview

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Status:
Withdrawn

Trial end date:
2018-12-20

Target enrollment:

Participant gender:

Summary

A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (>= Grade 3) select treatment-emergent adverse events (TEAEs).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate